Key result
In rat thrombosis models, YM-60828 exerted dose-dependent antithrombotic effects with a wider safety margin for bleeding time (ED2/ID50 ratio >30-fold greater than heparin) than comparator agents.
Why the study?
Does YM-60828 provide antithrombotic effects with less bleeding time prolongation compared to argatroban, heparin, and dalteparin in rat thrombosis models?
Population
Rat thrombosis models (venous thrombosis and arterio-venous shunt models)
Comparison
YM-60828 administered as an intravenous bolus vs Argatroban, heparin, and dalteparin administered…
Design
Preclinical
Authors
Loading...
May separate antithrombotic activity from bleeding risk in rat models; leaves open clinical translation of selective factor Xa inhibition.
Does YM-60828 provide antithrombotic effects with less bleeding time prolongation compared to argatroban, heparin, and dalteparin in rat thrombosis models?
YM-60828 is a novel factor Xa inhibitor that provides effective antithrombotic activity with a wider safety margin for bleeding compared to standard anticoagulants in preclinical models.
Sato et al. (1998) studied Thrombosis. YM-60828 vs. argatroban, heparin, and dalteparin was evaluated on Antithrombotic effects (ID50) and bleeding time prolongation (ED2). In rat thrombosis models, YM-60828 exerted dose-dependent antithrombotic effects with a wider safety margin for bleeding time (ED2/ID50 ratio >30-fold greater than heparin) than comparator agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: